Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.

You may also be interested in...



Organon, Pfizer Hope Hot Flashes Will Be Hot Market

Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.

Organon, Pfizer Hope Hot Flashes Will Be Hot Market

Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.

Organon Pharma Focus Is "Short Term": Strategic Decisions Later

Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel